Denali Therapeutics Announces FDA Has Selected Dnl126 (Etv:Sgsh) for Mps Iiia (Sanfilippo Syndrome Type a) for Start Pilot Program Intended to Accelerate Development of Rare Disease Therapies
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.